Remove tag regulations
article thumbnail

STAT+: CMS will use outcomes-based agreements in bid to help Medicaid pay for sickle cell gene therapies

STAT

In response to concerns over multimillion-dollar price tags for new gene therapies for sickle cell disease, the U.S. Two therapies recently approved by health regulators cost $2.2 million and $3.1 million, respectively, and have raised alarms over the ability of financially strapped state Medicaid programs to absorb the expense.

129
129
article thumbnail

STAT+: FDA cites Dr. Reddy’s for quality control problems at a biologics plant

STAT

Food and Drug Administration for a host of manufacturing violations at one of its plants in India, the latest instance in which the company was tagged by the regulator for quality-control problems. Reddy’s Laboratories, one of the world’s largest generic drugmakers, was cited by the U.S.

FDA 120
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

STAT+: FDA scolds Sun Pharmaceutical for serious quality control problems at a key plant in India

STAT

Food and Drug Administration for a host of serious manufacturing violations at a key plant in India, the latest instance in which the company was tagged by the regulator for quality-control problems. Sun Pharmaceutical, one of the world’s largest generic drugmakers, was scolded by the U.S.

FDA 91
article thumbnail

Haemophilia drug costing $3.5m per dose has been approved

Pharmafile

CSL Behring’s haemophilia B gene therapy has recently been approved by US regulators, however the treatment has an enormous price tag. Costing $3.5m per dose, the one-off infusion therapy has become the world’s most expensive medicine currently available.

72
article thumbnail

STAT+: Pharmalittle: We’re reading about Wegovy supplies, Biogen ditching Aduhelm, and more

STAT

In response to concerns over multi-million-dollar price tags for new gene therapies for sickle cell disease, the U.S.  Two therapies recently approved by health regulators cost $2.2 million and $3.1

86
article thumbnail

Cannabinoids receptors: popular preclinical target but banned in 137 countries

Pharmaceutical Technology

Collectively, cannabinoid receptors (CB1 and CB2) are currently the most popular targets in preclinical stage of development, with 391 drugs tagged in total. Despite the growing popularity of cannabinoid targets, the current regulatory landscape poses a challenge for cannabinoid-based drug developers and regulators.

article thumbnail

What can pharma marketing learn from other regulated industries?

pharmaphorum

In this article Joanna Carlish, managing director of financial services at Tag Americas , and Robb DeFilippis, Tag Americas’ managing director, life sciences, go head-to-head to discuss marketing within a regulated industry. How are regulated industries approaching the personalisation, or even hyper-personalisation, of content?